meiragtx stock price

* MeiraGTx anticipates reporting preliminary clinical data from the AAV-AQP1 program by the end of 2020.AAV-GAD for the Treatment of Parkinson’s Disease * Manufacturing of AAV-GAD material is ongoing at the Company’s London cGMP facility. as chief medical officer (CMO).A clinical immunologist by training, Dr. Zeldin brings more than 20 years of clinical, regulatory and industry experience to MeiraGTx, ranging from early-stage clinical development through Biologics License Application (BLA) filing and commercialization.“Dr. Prior to Acceleron, he was CMO of Belgium-based Ablynx NV, where he directed the Phase 3 development program and regulatory filings of caplacizumab, which has been approved for the treatment of thrombotic thrombocytopenic purpura in the U.S. and Europe. as Chief Medical OfficerMeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.

Minimum 15 minutes delayed. as Chief Medical OfficerMeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. Previously, he was CMO of Acceleron Pharma where he was instrumental in the preparation of the BLA for luspatercept which has been approved in the U.S. and Europe for the treatment of anemia associated with myelodysplastic syndromes and anemia associated with beta thalassemia.

This might drive the stock higher in the near term.MeiraGTx Reports Second Quarter 2020 Financial ResultsMeiraGTx Reports Second Quarter 2020 Financial ResultsMeiraGTx Reports Second Quarter 2020 Financial ResultsMeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. MGTX: Get the latest MeiraGTx stock price and detailed information including MGTX news, historical charts and realtime prices. Log in to see them here or sign up to get started.Create a list of the investments you want to track.Visit a quote page and your recently viewed tickers will be displayed here.MeiraGTx has been struggling lately, but the selling pressure may be coming to an end soon.MeiraGTx Positive Data, And Other News: The Good, Bad And Ugly Of BiopharmaIn a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Meiragtx Holdings (MGTX), with a price target of ...[...]Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:MeiraGTx Holdings PLC (MGTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. Copyright © 2020 MarketWatch, Inc. All rights reserved. “As we advance the MeiraGTx pipeline into late-stage development we are delighted to add Dr. Zeldin to our senior management team.”Prior to joining MeiraGTx, Dr. Zeldin was CMO of Immunovant. Today's High Today's Low 52 Week High 52 Week Low. Zeldin is an experienced drug developer with a distinguished track record in the design and implementation of successful clinical development strategies,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.

Do Wall Street analysts recommend investors buy shares of MeiraGTx?

Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.For more information, please visit www.meiragtx.com.Forward Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. Have Watchlists? In addition, the Company expects approximately $24.4 million in receivables from development partner Janssen in the next 90 days.

While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments.